X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on the advancement of the clinical development of TG4050, an individualized immunotherapy being developed for solid tumors. It is being evaluated in Phase I for the treatment of Squamous Cell Carcinoma of Head and Neck.
Lead Product(s): TG4050
Therapeutic Area: Oncology Product Name: TG4050
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: BostonGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration March 05, 2024
Details:
BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which is investigated in combination with KEYTRUDA® (pembrolizumab) for the treatment of solid tumors, including melanoma.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
BT-001 is an oncolytic virus generated using Transgene’s Invir.IO® platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which encode both a Treg-depleting human recombinant anti-CTLA-4 antibody and the human GM-CSF cytokine.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
TG6050 is an oncolytic virus derived from Transgene’s Invir.IO® platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody, with the potential to trigger a powerful antitumor immune response.
Lead Product(s): TG6050
Therapeutic Area: Oncology Product Name: TG6050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Under the termination, Transgene will regain the global rights to the intravenous oncolytic virus drug candidate, developed using Transgene’s next-generation viral Invir.IO™ platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 05, 2023
Details:
TG6050 is an oncolytic virus developed with Transgene’s Invir.IO™ platform for intravenous administration. TG6050 has been engineered to encode human IL-12, a cytokine that triggers a powerful antitumor immune response and a full length antiCTLA4 antibody.
Lead Product(s): TG6050
Therapeutic Area: Oncology Product Name: TG6050
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
TG4001 is a therapeutic cancer vaccine candidate using an attenuated and modified poxvirus (MVA) as a vector expressing the HPV16 E6 and E7 proteins (rendered non-oncogenic) interleukin-2.
Lead Product(s): Tipapkinogen sovacivec,Avelumab
Therapeutic Area: Oncology Product Name: TG4001
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
TG6002 is novel oncolytic virus that has been engineered to combine multiple mechanisms of action. It has been designed to,selectively replicate within cancer cells. This is due to deletion of viral genes encoding TK and RR.
Lead Product(s): TG6002,Fluocytosine
Therapeutic Area: Oncology Product Name: TG6002
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Under the terms of the supply agreement, MSD will provide pembrolizumab to be used in combination with BT-001 in the ongoing Phase 1/2a clinical trial. BT-001 is being co-developed as part of a 50/50 collaboration between Transgene and BioInvent.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioInvent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Details:
The initial data generated in Phase I part A demonstrated that BT-001 alone is well tolerated, with first signs of anti-tumor activity in a hard-to-treat population and confirmed the mechanism of action of BT‑001 as a single agent.
Lead Product(s): BT-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioInvent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
